NCT07502872 2026-03-31
TPG
Brown University
Phase 2 Not yet recruiting
Clinical Trials
13 trialsNCT04855695 2026-01-21
Avo In R/R And Previously Untreated MCL
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05929222 2025-12-24
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Phase 3 Recruiting
NCT06916767 2025-11-10
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Case Comprehensive Cancer Center
Phase 1 Recruiting
NCT02750670 2025-06-22
Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
University Health Network, Toronto
Phase 2 Completed
NCT06867536 2025-03-18
GLOHRT-01
Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT06549335 2024-10-15
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Ruijin Hospital
Phase 2 Not yet recruiting
NCT02529852 2024-09-19
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT06592170 2024-09-19
MZL-001
The First Hospital of Jilin University
Phase 1/2 Recruiting
NCT05848765 2023-11-29
REFRACT
University of Birmingham
Phase 2 Recruiting
NCT05899621 2023-06-12
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
Ruijin Hospital
Recruiting
NCT03276468 2023-01-10
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT01659099 2018-03-07
GAINED
The Lymphoma Academic Research Organisation
Phase 3 Terminated